These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 38247617)

  • 1. New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.
    Nau R; Seele J; Eiffert H
    Antibiotics (Basel); 2024 Jan; 13(1):. PubMed ID: 38247617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
    Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
    Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Aminoglycosides in Adults.
    LeBras M; Chow I; Mabasa VH; Ensom MH
    Neurocrit Care; 2016 Dec; 25(3):492-507. PubMed ID: 27043949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraventricular and lumbar intrathecal administration of antibiotics in postneurosurgical patients with meningitis and/or ventriculitis in a serious clinical state.
    Remeš F; Tomáš R; Jindrák V; Vaniš V; Setlík M
    J Neurosurg; 2013 Dec; 119(6):1596-602. PubMed ID: 23952688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New Antibiotics for Treatment of Highly Resistant Gram-negative Bacteria].
    Probst-Kepper M; Geginat G
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Jul; 53(7-08):529-542. PubMed ID: 30036899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
    Wright H; Bonomo RA; Paterson DL
    Clin Microbiol Infect; 2017 Oct; 23(10):704-712. PubMed ID: 28893690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults.
    Ng K; Mabasa VH; Chow I; Ensom MH
    Neurocrit Care; 2014 Feb; 20(1):158-71. PubMed ID: 23090839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.
    Aslan AT; Akova M
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.
    Kaye KS; Naas T; Pogue JM; Rossolini GM
    Infect Dis Ther; 2023 Mar; 12(3):777-806. PubMed ID: 36847998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.
    Jean SS; Liu IM; Hsieh PC; Kuo DH; Liu YL; Hsueh PR
    Int J Antimicrob Agents; 2023 May; 61(5):106763. PubMed ID: 36804370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraventricular CNS treatment with Colistin-Tigecycline combination: A case series.
    Tsolaki V; Karvouniaris M; Manoulakas E; Kotlia P; Karadontas V; Fotakopoulos G; Zakynthinos E; Makris D
    J Crit Care; 2018 Oct; 47():338-341. PubMed ID: 30097260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.